Prophylaxis for Latent Tuberculosis Infection Prior to Anti–Tumor Necrosis Factor Therapy in Low‐Risk Elderly Patients With Rheumatoid Arthritis: A Decision Analysis
- 1 November 2013
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 65 (11) , 1722-1731
Abstract
Objective: To determine if low‐risk elderly patients with rheumatoid arthritis (RA) who screen positive for latent tuberculosis (TB) infection prior to anti–tumor necrosis factor (anti‐TNF) therapy should be given isoniazid (INH).Methods: A Markov model was developed. The base case was a patient age 65 years with RA starting anti‐TNF therapy with a positive tuberculin skin test (TST) finding of 5–9 mm, who was born in a country with low TB prevalence and had no other TB risk factors. The decision was 9 months of INH or not. The primary outcome was quality‐adjusted life expectancy. Multiple sensitivity analyses were performed.Results: No prophylaxis was favored, with a gain of 1.1 quality‐adjusted life days, but the decision was sensitive to several variables. Prophylaxis was favored for patients ages 2.5, if the RR with anti‐TNF therapy was >5.8, or if the utility associated with INH therapy was >0.98. Prophylaxis was also preferred for patients with a TST result >10 mm and for patients from higher risk countries. If 6 months of INH or 4 months of rifampin were used, prophylaxis was preferred, providing that therapy reduced the risk of TB reactivation by >47% and >27%, respectively.Conclusion: Withholding prophylaxis prior to anti‐TNF therapy may be reasonable for low‐risk elderly RA patients with a TST finding of 5–9 mm, although the decision is sensitive to patient preferences. For patients age 10 mm, prophylaxis is preferred.Keywords
This publication has 36 references indexed in Scilit:
- Adverse events associated with treatment of latent tuberculosis in the general populationCanadian Medical Association Journal, 2011
- A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis RegistriesSeminars in Arthritis and Rheumatism, 2010
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals of the Rheumatic Diseases, 2010
- Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)Annals of the Rheumatic Diseases, 2010
- Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registryArthritis & Rheumatism, 2009
- Costs and Cost-effectiveness of Four Treatment Regimens for Latent Tuberculosis InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2009
- American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritisArthritis Care & Research, 2008
- Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinicAnnals of the Rheumatic Diseases, 2008
- Increased risk of tuberculosis in patients with rheumatoid arthritis in JapanAnnals of the Rheumatic Diseases, 2006
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001